Rubidium in Psychiatry: Research Implications

PARVIZ MALEK-AHMADI AND JOHN A. WILLIAMS
Department of Psychiatry, School of Medicine
Texas Tech University Health Sciences Center, Lubbock, TX 79430

THE introduction of antidepressant drugs represents a major advance in psychiatry. However, the search for new antidepressant agents continues and new drugs have been or are being introduced. Some naturally occurring substances also have been claimed to have antidepressant activity and implicated in the pathogenesis of major affective disorders. Among such substances, rubidium has been investigated in a number of studies. It is the purpose of this brief review to re-examine the role of rubidium as a potential antidepressant and a research tool in the psychopharmacology of affective disorders and schizophrenia.

Rubidium is one of the alkali metals of the group IA in the periodic table of the elements. It is widespread in nature, found in plant, animal, and human tissues. Among the food items soybeans are quite rich in rubidium [9]. In the United States, the mean dietary daily intake of rubidium for adult male and female subjects is about 2.53 and 1.8 mg respectively [19,20]. Trace amounts of rubidium have not been found to be toxic in animals [10]. Moreover, it has been proposed that rubidium may be an essential dietary factor [9]. Siegers et al. [14] have suggested that rubidium content in rats is genetically determined and is not affected by the nutritional status. There is also evidence to suggest that the skin content of rubidium in humans is negatively correlated with age [15].

Rubidium salts have no clinical use in medicine. They, however, have been administered to patients with affective and schizophrenic disorders in a number of studies.

RUBIDIUM AND AFFECTIVE DISORDERS

Lithium and rubidium have some contrasting neurochemical, neurophysiological, pharmacological and behavioral effects in laboratory animals.

In 1971, Fieve et al. [7] hypothesized that rubidium may have some application in the treatment of affective disorders. The researchers conducted the first metabolically controlled study in which rubidium chloride was administered to healthy subjects and affective disorder patients. Although no definite conclusion regarding the antidepressant properties of rubidium could be reached, the study provided a groundwork for subsequent trials and a number of studies have been conducted. Fieve and Jamison [8] have recently reviewed these studies and have alluded to the methodological problems.

The role of rubidium as a potential antidepressant obviously requires further investigation. Rubidium, however, may have some relevance to the treatment of affective disorders with lithium. It has been suggested that rubidium may affect the response of bipolar patients to lithium. McClure et al. [12] have hypothesized that high serum rubidium levels are found in bipolar patients who respond favorably to lithium. This is an intriguing hypothesis when one considers the contrasting effects of rubidium and lithium and the inconsistent results with the other potential biological predictors [14]. There are several studies concerning blood rubidium levels in patients with affective disorders and normal subjects [1, 5, 6, 18, 19, 20, 21]. Aside from methodological problems associated with the techniques, large variabilities in plasma rubidium and its urinary excretion have been noted [13,19].

In a recent study, Zizolfi et al. [22] have measured basal rubidium blood levels in patients with affective disorders, schizophrenia and normal subjects. The researchers have not found a significant difference between the rubidium levels of the patients population and those of normal controls. No significant differences were found between males and females. Furthermore, the age did not appear to have any effect on the basal rubidium blood levels. The above study, although the first in its kind, has some limitations since there were only two patients diagnosed as having bipolar disorder. The role of rubidium as a predictor of lithium response would have to be investigated in future studies involving a larger number of patients.
RUBIDIUM AND SCHIZOPHRENIA

The reported antidepressant activity of rubidium in patients with affective disorders led Chouinard and Annable to hypothesize that the agent may be of some therapeutic value in improving affective symptoms of patients suffering from chronic schizophrenia [2]. In 1977 Chouinard and Annable [2] in a double-blind, placebo-controlled study lasting for nine weeks investigated the effects of rubidium chloride in eighteen hospitalized chronic schizophrenic patients. Rubidium improved the negative symptoms of the patients but had no effect on the positive symptoms. In a subsequent study lasting for twelve weeks, rubidium chloride was administered to twenty-four patients. Once again, there was an improvement in the negative symptoms, but it was preceded by an exacerbation of the positive symptoms [4]. These findings are best explained by desensitization of supersensitive dopamine receptors. Rubidium may increase the availability of dopamine at the receptor sites (initial exacerbation) and this is followed by desensitization of dopaminergic receptors. Rubidium may improve the negative symptoms but it was preceded by an exacerbation of the positive symptoms [4]. These findings are consistent with the dopamine-deficiency hypothesis of schizophrenia proposed by Chouinard and Jones [3].

REFERENCES